TPD52 Antibody

What is TPD52 and why is it a significant target for cancer research?

TPD52 (Tumor Protein D52) is a proto-oncogene frequently overexpressed in multiple cancer types and actively involved in malignant transformation. It leads to increased proliferation and metastasis across various human adult and pediatric malignancies . The significance of TPD52 as a research target stems from several key characteristics:

• Located on chromosome 8q21, TPD52 is frequently amplified and overexpressed in prostate and breast carcinomas

• Contains coiled-coil motifs that facilitate critical protein-protein interactions

• Functions in the regulation of secretory pathways in plasma cells

• Binds to annexin VI in a calcium-dependent manner, indicating roles in exocytosis and calcium-regulated functions

• Serves as an independent prognostic biomarker, particularly in breast cancer

TPD52 overexpression has been reproducibly associated with poorer outcomes in breast cancer patients and early lethality in prostate cancer patients, making it both a prognostic marker and potential therapeutic target .

What detection methods can be employed with TPD52 antibodies?

TPD52 antibodies can be utilized across multiple detection platforms with varying sensitivity and applications:

The choice of detection method should be guided by the specific research question. For example, co-localization studies examining TPD52 interactions with PLIN2 at lipid droplets are best performed using immunofluorescence with super-resolution STED microscopy .

How should TPD52 antibodies be validated for research applications?

Proper validation of TPD52 antibodies is critical for generating reliable research data:

• Specificity testing: Confirm antibody recognizes TPD52 but not related family members (TPD52L1, TPD52L2) through:

  • Western blot analysis against recombinant proteins

  • Testing in cell lines with known expression levels

  • Knockdown/knockout validation to confirm signal reduction

• Cross-reactivity assessment: If working across species, validate antibody reactivity in target species:

  • Human TPD52 and murine orthologue (mD52) share 86% amino acid identity

  • Test antibodies against both human and mouse samples when conducting comparative studies

• Controls and validation markers:

  • Use positive control tissues (prostate, breast cancer specimens with known TPD52 overexpression)

  • Include negative controls (primary antibody omission)

  • Consider using the immunoreactive score (IRS) system for quantification in IHC applications

Rigorous antibody validation ensures experimental reproducibility and the ability to effectively compare results across different studies focusing on TPD52's role in cancer progression.

What are the critical parameters for immunohistochemical detection of TPD52 in cancer tissues?

For optimal immunohistochemical detection of TPD52 in cancer tissues:

• Tissue preparation:

  • Follow standard LSAB protocol (Dako) for consistent results

  • Ensure proper fixation (typically 10% neutral buffered formalin)

  • Consider antigen retrieval methods (citrate buffer pH 6.0 or EDTA buffer pH 9.0)

• Antibody selection and application:

  • Primary antibody: Rabbit anti-human TPD52 has shown reliable results (e.g., Abcam ab182578)

  • Secondary antibody: Biotinylated anti-rabbit (e.g., Dako system)

  • Working dilution: Generally 1:50-1:200 for IHC applications

• Evaluation metrics:

  • TPD52 protein is detected primarily in plasma membrane and cytoplasm

  • Use semi-quantitative scoring based on immunoreactive score (IRS)

  • Consider both staining intensity and percentage of positive cells

• Controls:

  • Include tissue microarrays with known TPD52 expression

  • Include primary antibody omission controls

  • Consider using normal adjacent tissue for expression comparison

This methodological approach ensures consistent and reproducible assessment of TPD52 expression across different cancer types and patient samples.

How can protein-protein interactions with TPD52 be effectively studied using antibody-based approaches?

Investigating TPD52 protein interactions requires specialized techniques:

• Co-immunoprecipitation (Co-IP):

  • TPD52-LKB1 interaction has been successfully demonstrated through reciprocal Co-IP

  • Protocol: Immunoprecipitate with anti-TPD52 antibody, then immunoblot for interaction partners (or vice versa)

  • Both endogenous and exogenous (FLAG-tagged TPD52) approaches have been validated

• Proximity ligation assay (PLA):

  • Useful for detecting in situ protein-protein interactions

  • Can visualize interactions between TPD52 and binding partners like AMPKα

• Double immunofluorescence with confocal microscopy:

  • Successfully used to confirm TPD52-LKB1 co-localization in prostate cancer cell lines (LNCaP and VCaP)

  • Analysis should include correlation between fluorescence signals

  • Super-resolution STED microscopy provides enhanced visualization of co-localization at subcellular structures

• GST pull-down assays:

  • Effective for mapping interaction domains

  • Has identified direct binding between TPD52 and AMPKα1/α2 (but not other AMPK subunits)

  • Can determine which regions of TPD52 are responsible for specific interactions

The most robust approach combines multiple methods to validate interactions, as demonstrated in studies examining TPD52-LKB1 and TPD52-AMPK interactions .

What are common challenges in TPD52 antibody applications and how can they be overcome?

When studying TPD52 in different cancer contexts, consider that TPD52 may form complexes with different partners depending on the cancer type. For example, in prostate cancer, TPD52-LKB1 interaction affects AMPK signaling , while in other cancers, different interaction networks may predominate.

What evidence supports TPD52 as a potential cancer vaccine antigen?

Preclinical studies provide compelling evidence for TPD52 as a cancer vaccine antigen:

• Overexpression profile:

  • TPD52 is universally overexpressed across multiple cancer types

  • Involved in transformation, proliferation, and metastasis

  • Critical for tumor cell survival

• Immunogenicity:

  • Vaccination with murine orthologue (mD52) elicits CD8 cytotoxic T cells (CTLs) against TPD52-overexpressing tumor cells

  • Multiple vaccine formulations have demonstrated efficacy in murine models

• Preclinical vaccine efficacy:

  • Protection levels ranging from 30-80% against primary tumors

  • Up to 100% protection against secondary tumors and metastasis

  • Enhanced protection (70-80%) when combined with regulatory T cell depletion

• Safety profile:

  • No autoimmunity observed despite TPD52 expression in normal tissues

  • CD8 IL-10 T cells may provide protective regulation

The table below summarizes key preclinical vaccine studies from multiple mouse models:

These findings collectively support TPD52 as a promising candidate for cancer vaccine development with a favorable risk-benefit profile .

What methodological approaches are optimal for studying TPD52 vaccine responses?

For studying TPD52 vaccine responses in experimental models:

• T cell response characterization:

  • Flow cytometry for phenotypic analysis (CD8, IFN-γ, IL-10)

  • ELISPOT assays to quantify antigen-specific T cells

  • CTL assays to measure tumor cell killing capacity

  • MHC restriction analysis (H-2Kd and H-2Kb restricted epitopes have been identified)

• Vaccine formulation optimization:

  • DNA vaccines (mD52 or hD52 coding sequences)

  • Protein vaccines (recombinant mD52 protein)

  • Prime-boost strategies (DNA prime + protein boost)

  • Adjuvant selection (ODN-alum, ODN-IFA, rGM-CSF)

• Regulatory T cell analysis:

  • CD4+CD25+ Treg depletion enhances vaccine efficacy

  • CD8+IL-10+ T cells emerge following vaccination and may play regulatory role

  • CCR8 targeting may enhance tumor rejection by inhibiting CD8 IL-10 Tregs

• Tumor protection assays:

  • Primary tumor challenges (subcutaneous)

  • Secondary tumor challenges (evaluate memory responses)

  • Spontaneous metastasis monitoring (lung metastasis models)

• Autoimmunity assessment:

  • Histopathological analysis of normal tissues

  • Autoantibody detection

  • Clinical observation for adverse events

These methodological approaches have been validated across multiple mouse strains (BALB/c, C57BL/6) and tumor models (sarcomas, prostate cancer), providing a robust framework for TPD52 vaccine development .

How can TPD52 antibodies be effectively used to study its role in AMPK signaling and cancer metabolism?

TPD52 has been identified as a regulator of AMPK signaling in cancer, and antibody-based approaches are essential for investigating this relationship:

• Co-immunoprecipitation for pathway interactions:

  • TPD52 directly binds to AMPKα1 and α2 subunits but not β or γ subunits

  • Protocol: Use anti-TPD52 antibody for immunoprecipitation followed by immunoblotting for AMPKα subunits

• Domain mapping approaches:

  • GST pull-down assays with truncation mutants

  • TPD52 deletion mutant D4 (deletion amino acid residues 1–61) abolishes binding with AMPKα

  • Essential for determining functional interaction domains

• Phosphorylation status analysis:

  • Western blotting with phospho-specific antibodies

  • Key targets: pAMPK (Thr172), pLKB1 (Ser428), and downstream targets pACC1 and pTSC2

  • TPD52 overexpression reduces pLKB1 and pAMPK levels, while TPD52 knockdown increases these phosphorylation events

• Functional assays:

  • AMPK activation (AICAR treatment) downregulates TPD52 expression in prostate cancer cells

  • AMPK inhibition (Compound C) increases TPD52 expression

  • GSK3β inhibition (LiCl) attenuates AICAR-induced TPD52 downregulation

A model of TPD52-AMPK regulatory circuit:

• TPD52 interacts with LKB1, inhibiting its kinase activity and auto-phosphorylation

• This interaction reduces AMPK activation (decreased pAMPK)

• AMPK activation in turn downregulates TPD52 via GSK3β

• This creates a regulatory feedback loop in cancer cells

This methodological framework allows researchers to dissect the complex relationship between TPD52 and metabolic regulation in cancer cells.

What controls and validation steps are critical when studying TPD52's subcellular localization at lipid droplets?

When investigating TPD52's association with lipid droplets:

• Co-localization controls:

  • PLIN2 is a reliable marker for lipid droplets that co-localizes with TPD52

  • Include BODIPY staining for neutral lipid droplet confirmation

  • BFA treatment (5h) significantly increases TPD52 detection at lipid droplets

• Microscopy considerations:

  • Standard confocal microscopy may be insufficient to resolve detailed structures

  • Super-resolution STED microscopy provides enhanced visualization of TPD52-PLIN2 co-localization at lipid droplets

  • Z-stack imaging ensures complete capture of three-dimensional structures

• Quantification methods:

  • Measure co-localization using established coefficients (Pearson's, Mander's)

  • Quantify the percentage of TPD52-positive ring structures that co-stain with PLIN2

  • Statistical analysis should compare treated vs. control conditions

• Experimental manipulations:

  • Treat cells with Brefeldin A (BFA) to induce TPD52 recruitment to lipid droplets

  • Use DMSO as vehicle control

  • Consider time-course experiments to track dynamic recruitment (e.g., 0h, 5h BFA treatment)

• Antibody validation for subcellular applications:

  • Confirm antibody specificity in immunofluorescence applications

  • Use multiple antibodies targeting different TPD52 epitopes when possible

  • Include isotype controls to rule out non-specific binding

This systematic approach has revealed that TPD52 shows delayed recruitment to lipid droplets compared to other lipid droplet-associated proteins, suggesting a specific temporal role in lipid metabolism that may be relevant to cancer biology .